Navigation Links
Resverlogix Commences Phase 2 Atherosclerosis Clinical Trial
Date:12/22/2009

taining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and additional risk factors discussed in other documents we file from time to time with securities authorities, which are available through SEDAR at www.sedar.com. Additionally, risks and uncertainties are discussed in detail in the December 15, 2009 MD&A. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

SOURCE Resverlogix Corp.


'/>"/>
SOURCE Resverlogix Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Resverlogix Updates Shareholders on Accelerated Clinical Trial Plan
2. Resverlogix Appoints A. Brad Cann as Chief Financial Officer
3. Resverlogix RVX-208 Second Clinical Trial Demonstrates Success on Key Reverse Cholesterol Transport Markers
4. Resverlogix Phase 1b/2a Study Meets Primary Endpoint
5. Resverlogixs Success in Inflammation Program Results in 2 Patents Filed
6. Resverlogix Provides Quarterly Update
7. Resverlogix Board of Directors Update
8. Resverlogix Advances to Second Arm of Phase 1b/2a Clinical Trial
9. Resverlogix Announces Closing of Debt Redemption
10. Resverlogix Eliminates Sixty Percent of Remaining Debt
11. Resverlogix Issues a Management Statement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... -- US-Australian drug discovery company, Novogen Limited (ASX: NRT; ... to progressing its ground-breaking technology platforms to Phase 1 ... the Company delivers the best value for shareholders. ... said the Company currently had an extensive program of ... and academic partnerships and initiatives, and he was working ...
(Date:7/29/2015)... ... July 29, 2015 , ... G-CON Manufacturing, Inc., the leading ... 2nd generation cell therapy POD® design. The 2nd generation portfolio not only delivers ... new POD® design. , “G-CON first offered our miniPOD CT product line ...
(Date:7/29/2015)... SAN DIEGO , July 29, 2015  Pfenex ... quarter 2015 financial results will be released on Thursday, ... 8:30 am Eastern Time, Pfenex management will host a ... a business update.  A press release outlining the financial ... to the call. Please call 1-866-376-8058 (US) ...
(Date:7/29/2015)... ... 29, 2015 , ... Finding gooey or crusty material in the corner of ... a considerable number of terms in popular use to describe it, ophthalmologists call it ... of mucus, blood cells, skin cells and dust, but until now there has been ...
Breaking Biology Technology:Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 3Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 2What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 3What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 4
... Researchers in India have demonstrated that producing nanoscopic crystals of ... by the gut even if the drug is not soluble ... the medicinal drugs being developed by the pharmaceutical industry dissolve ... a major problem for administering such drugs as it means ...
... ANGELES, Oct. 6 Entertain and interact.  That,s ... . ( www.drfresh.com ), the creator of the ... company behind the successful revival of the ... http://photos.prnewswire.com/prnh/20101006/LA77977LOGO ) (Logo:   http://www.newscom.com/cgi-bin/prnh/20101006/LA77977LOGO ) ...
... Inc. Against the Company And Certain of Its Subsidiaries ... ... --> ... var s = ,; var first_result; // Results are keyed by longUrl, so we need to ...
Cached Biology Technology:Nano drugs 2A 'Fresh' Approach to Marketing: Dr. Fresh™, Inc. Goes Guerilla With Internet-Based Campaigns 2Angiotech Pharmaceuticals, Inc. Announces Commencement of Arbitration and Litigation Proceedings by QSR Holdings, Inc. Against the Company And Certain of Its Subsidiaries 2Angiotech Pharmaceuticals, Inc. Announces Commencement of Arbitration and Litigation Proceedings by QSR Holdings, Inc. Against the Company And Certain of Its Subsidiaries 3Angiotech Pharmaceuticals, Inc. Announces Commencement of Arbitration and Litigation Proceedings by QSR Holdings, Inc. Against the Company And Certain of Its Subsidiaries 4Angiotech Pharmaceuticals, Inc. Announces Commencement of Arbitration and Litigation Proceedings by QSR Holdings, Inc. Against the Company And Certain of Its Subsidiaries 5Angiotech Pharmaceuticals, Inc. Announces Commencement of Arbitration and Litigation Proceedings by QSR Holdings, Inc. Against the Company And Certain of Its Subsidiaries 6Angiotech Pharmaceuticals, Inc. Announces Commencement of Arbitration and Litigation Proceedings by QSR Holdings, Inc. Against the Company And Certain of Its Subsidiaries 7Angiotech Pharmaceuticals, Inc. Announces Commencement of Arbitration and Litigation Proceedings by QSR Holdings, Inc. Against the Company And Certain of Its Subsidiaries 8Angiotech Pharmaceuticals, Inc. Announces Commencement of Arbitration and Litigation Proceedings by QSR Holdings, Inc. Against the Company And Certain of Its Subsidiaries 9
(Date:7/9/2015)... , July 9, 2015  Synaptics Inc. (NASDAQ: SYNA ... today that it will report financial results for the ... 30, 2015 after the close of market. The company ... investors at 2:00 p.m. PT (5:00 p.m. ET), during ... To participate on the live call, analysts and investors ...
(Date:7/8/2015)... , N.J. and NEW YORK , July ... Guidepoint today announced BD & Guidepoint ... companies with free access to Guidepoint,s expert network services. ... that are developing cutting-edge technologies to improve healthcare delivery ... Guidepoint research manager, each start-up entrepreneur will be able ...
(Date:7/7/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... commerce market announces a revised version of one of its first ... air on CNBC in New York , ... San Francisco metro areas.    ... ability to replace all the cards in your wallet and keep ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3
... suffer from persistent wounds open sores that never seem ... The bedridden elderly and infirm are prone to painful and ... by a lack of blood flow to the extremities. ... Aviv University,s Department of Molecular Microbiology and Biotechnology. To solve ...
... CAMDEN Since the advent of the Human Genome Project ... There is a growing demand to fine-tune genomic codes, which ... how those ingredients function. A Rutgers UniversityCamden ... a database for quick "background checks" on all known enzyme ...
... Researchers from Turku, Finland, have identified a blood-flow glucose ... results of a study published in Clinical Cancer ... Cancer Research. Based on these findings, they ... might provide more important information about a tumor than ...
Cached Biology News:Washing away painful wounds 2Rutgers-Camden developing enzyme function database 2Blood-flow metabolism mismatch predicts pancreatic tumor aggressiveness 2